Ophthalmic components

JP7863278B2Active Publication Date: 2026-05-21SYDNEXIS INC
View PDF 4 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
SYDNEXIS INC
Filing Date
2022-01-12
Publication Date
2026-05-21

AI Technical Summary

Technical Problem

Pharmaceutical preparations, particularly ophthalmic compositions containing muscarinic antagonists like atropine, face stability issues due to decomposition of active ingredients, leading to inconsistent efficacy and potential side effects from low pH ranges, especially at low concentrations.

Method used

Formulating ophthalmic compositions with a pH range of 4.2 to 7.9 and incorporating deuterated water to stabilize muscarinic antagonists, maintaining at least 80% efficacy over extended periods, and reducing systemic absorption.

Benefits of technology

The compositions maintain high muscarinic antagonist concentrations and stability, minimizing side effects and ensuring consistent therapeutic effects over several years, while reducing systemic exposure.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007863278000041
    Figure 0007863278000041
  • Figure 0007863278000042
    Figure 0007863278000042
  • Figure 0007863278000043
    Figure 0007863278000043
Patent Text Reader

Abstract

To provide an ophthalmic composition containing a muscarinic antagonist that is stable for a long period of time when stored at room temperature. [Solution] An ophthalmic composition with a pD of approximately 4.2 to approximately 7.9 is provided, containing approximately 0.001 wt% to approximately 0.05 wt% of a muscarinic antagonist and deuterated water.
Need to check novelty before this filing date? Find Prior Art